The day continued with insightful remarks between our moderators and notable company management, including:

• uniQure (#QURE) | Moderated by Kristen Kluska – Matthew Kapusta (CEO) walked through uniQure’s gene therapy approaches across multiple diseases including recent data in Huntington’s disease.

• LifeMD (#LFMD) | Moderated by Sarah James – Marc Benathen (CFO) discussed leveraging GLP-1 market growth via the company’s virtual weight loss clinic and virtual primary care products.

• Mainz Biomed (#MYNZ) | Moderated by Ross Osborn, CFA – Guido Baechler (CEO) discussed MYNZ’s recent positive clinical trial results, as well as the company’s path to commercialization in the U.S. for ColoAlert, the company’s flagship product.

• Verve Therapeutics (#VERV) | Moderated by Rick Bienkowkski, Ph.D. – Sekar Kathiresan, M.D. (CEO) walked through the company’s clinical strategy for developing VERVE-101 and highlighted the opportunity for “one-and-done” therapies for the treatment of cardiovascular disease.

#Cantor #CantorFitzgerald #CantorHealthcare #CantorGlobalHealthcare2023